uniQure (QURE) Competitors $9.65 +0.48 (+5.23%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$9.65 0.00 (0.00%) As of 04/15/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. BHVN, TARS, GMTX, AAPG, BLTE, NAMS, MTSR, ARQT, RXRX, and DNLIShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Biohaven (BHVN), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), Metsera (MTSR), Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Biohaven Tarsus Pharmaceuticals Gemini Therapeutics Ascentage Pharma Group International Belite Bio NewAmsterdam Pharma Metsera Arcutis Biotherapeutics Recursion Pharmaceuticals Denali Therapeutics uniQure (NASDAQ:QURE) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Which has preferable earnings & valuation, QURE or BHVN? uniQure has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M19.24-$308.48M-$4.93-1.96BiohavenN/AN/A-$408.17M-$9.39-1.98 Is QURE or BHVN more profitable? Biohaven has a net margin of 0.00% compared to uniQure's net margin of -837.80%. uniQure's return on equity of -188.82% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-837.80% -188.82% -32.17% Biohaven N/A -225.12%-158.89% Do analysts prefer QURE or BHVN? uniQure presently has a consensus price target of $38.80, suggesting a potential upside of 302.07%. Biohaven has a consensus price target of $62.77, suggesting a potential upside of 238.12%. Given uniQure's higher probable upside, research analysts plainly believe uniQure is more favorable than Biohaven.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82Biohaven 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Do insiders and institutionals have more ownership in QURE or BHVN? 78.8% of uniQure shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 16.0% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, QURE or BHVN? uniQure has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Does the media prefer QURE or BHVN? In the previous week, Biohaven had 8 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Biohaven and 2 mentions for uniQure. Biohaven's average media sentiment score of 0.55 beat uniQure's score of 0.43 indicating that Biohaven is being referred to more favorably in the news media. Company Overall Sentiment uniQure Neutral Biohaven Positive Does the MarketBeat Community believe in QURE or BHVN? uniQure received 251 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 70.57% of users gave uniQure an outperform vote while only 67.33% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformuniQureOutperform Votes65770.57% Underperform Votes27429.43% BiohavenOutperform Votes40667.33% Underperform Votes19732.67% SummaryuniQure beats Biohaven on 9 of the 17 factors compared between the two stocks. Remove Ads Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$521.84M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.956.7921.7317.82Price / Sales19.24225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book2.225.866.464.00Net Income-$308.48M$141.86M$3.20B$247.23M7 Day Performance5.35%4.50%2.86%1.45%1 Month Performance-32.04%-12.65%-8.55%-6.24%1 Year Performance105.32%-11.06%10.47%0.60% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure2.1775 of 5 stars$9.65+5.2%$38.80+302.1%+103.6%$521.84M$27.12M-1.95500Short Interest ↑Gap DownBHVNBiohaven3.4868 of 5 stars$17.86-3.9%$62.77+251.4%-58.5%$1.82BN/A-1.91239TARSTarsus Pharmaceuticals2.9585 of 5 stars$47.49+1.0%$63.67+34.1%+40.6%$1.82B$182.95M-12.4650Positive NewsGMTXGemini TherapeuticsN/A$41.22-9.9%N/A+26.5%$1.79BN/A-41.2230Gap UpHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$20.40-2.6%N/AN/A$1.78B$980.65M0.00600Positive NewsGap DownBLTEBelite Bio2.8693 of 5 stars$55.67-2.2%$96.67+73.6%+61.8%$1.77BN/A-50.1510Short Interest ↓NAMSNewAmsterdam Pharma2.2646 of 5 stars$15.86+0.3%$43.33+173.2%-18.6%$1.74B$45.56M-6.104Short Interest ↑MTSRMetseraN/A$16.45-2.1%$47.00+185.7%N/A$1.73BN/A0.0081High Trading VolumeARQTArcutis Biotherapeutics2.924 of 5 stars$14.30-2.9%$18.80+31.5%+30.7%$1.70B$196.54M-7.99150RXRXRecursion Pharmaceuticals2.1163 of 5 stars$4.20-0.9%$8.25+96.4%-27.6%$1.69B$58.49M-2.75400News CoverageHigh Trading VolumeDNLIDenali Therapeutics4.1325 of 5 stars$11.60-1.5%$37.20+220.7%-26.2%$1.68B$330.53M-4.20430Analyst Revision Remove Ads Related Companies and Tools Related Companies BHVN Alternatives TARS Alternatives GMTX Alternatives AAPG Alternatives BLTE Alternatives NAMS Alternatives MTSR Alternatives ARQT Alternatives RXRX Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QURE Stock Free QURE Stock Alerts